Agenus
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Agenus sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).
Agenus: 24 sponsored US clinical trials, none currently recruiting.
Agenus sponsors 24 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 3 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 2 trials.
Top-decile sponsor footprint
Agenus ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (68.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
24 total, page 1 of 1
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
NCT03894215
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272
Study of AGEN1571 in Participants With Advanced Solid Tumors
NCT05377528
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
NCT05025085
A Study in Subjects With Advanced Solid Tumors
NCT04156100
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
NCT04121676
Phase 1a Study to Evaluate Immunogenicity of ASV®
NCT03673020
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
NCT03495882
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
NCT03104699
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
NCT02992977
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
NCT02694822
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
NCT01687595
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
NCT01147536
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
NCT00316511
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
NCT00231049
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
NCT00126178
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
NCT00058747
Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
NCT00082459
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
NCT00039000
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
NCT00033904
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
NCT00081809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 9 |
| Phase 3 | 3 |
How the Agenus early-phase archive is shaped
24 indexed studies, none listed as recruiting (0% open); 13 completed (54%).
Phase mix: 3 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Agenus: archived-pipeline peers nationwide
Peers matched on 24 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Agenus sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 24 archived trials
- Acrotech Biopharma · 24 trials · 8% recruiting
- Akebia Therapeutics · 24 trials · 4% recruiting
- Blueprint Medicines Corporation · 24 trials · 25% recruiting
- Concert Pharmaceuticals · 24 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Agenus page
24 registered trials is a research-attention snapshot, not an endorsement of Agenus or any single study.
- None of Agenus's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Cancer is the condition Agenus studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Agenus pipeline card: 24 registered trials from official public datasets.Report a data error.